<p>Drugmaker Pfizer Inc said on Tuesday it was not yet ready to release data from the late-stage trial of the Covid-19 vaccine candidate it is developing with Germany's BioNTech SE.</p>.<p>Pfizer's CEO Albert Bourla has said the company could release data on whether or not the vaccine works as early as this month, but the company said in a presentation that the independent data monitoring board which will determine whether or not the trial has been successful has not conducted any interim efficacy analyses yet.</p>.<p>Shares were flat at $37.93 before the opening bell.</p>.<p>U.S. President Donald Trump had said a vaccine could be available before the Nov. 3 election, but in recent weeks his administration has emphasized that one will be ready this year.</p>.<p>Pfizer hopes to be the first U.S. drugmaker to unveil successful data from a late-stage Covid-19 vaccine trial, ahead of rival Moderna Inc. Pfizer and BioNTech launched their 44,000 volunteer phase 3 study of their vaccine candidate in late July.</p>.<p>The data monitoring board is scheduled to make its first assessment of the vaccine's performance after 32 participants in the trial become infected with the novel coronavirus.</p>.<p>As the pandemic crimps demand for certain Pfizer therapies and damages global economies, investors are keenly focused on seeing the late-stage study data of the vaccine candidate being developed with BioNTech.</p>.<p>Pfizer reported quarterly earnings that beat estimates by one cent, helped by better-than-expected sales of its cancer drug Ibrance.</p>.<p>Overall sales fell 4.3% in the third quarter, hurt by a plunge in sales of its off-patent pain drug Lyrica and a $500 million hit to sales from the Covid-19 pandemic.</p>.<p>Sales of cancer drug Ibrance grew 6% to $1.36 billion, beating analyst estimates of $1.39 billion, despite increased competition from Eli Lilly's Verzenio.</p>.<p>Excluding items, Pfizer earned 72 cents per share, beating analysts estimates of 71 cents per share, according to IBES data from Refinitiv.</p>
<p>Drugmaker Pfizer Inc said on Tuesday it was not yet ready to release data from the late-stage trial of the Covid-19 vaccine candidate it is developing with Germany's BioNTech SE.</p>.<p>Pfizer's CEO Albert Bourla has said the company could release data on whether or not the vaccine works as early as this month, but the company said in a presentation that the independent data monitoring board which will determine whether or not the trial has been successful has not conducted any interim efficacy analyses yet.</p>.<p>Shares were flat at $37.93 before the opening bell.</p>.<p>U.S. President Donald Trump had said a vaccine could be available before the Nov. 3 election, but in recent weeks his administration has emphasized that one will be ready this year.</p>.<p>Pfizer hopes to be the first U.S. drugmaker to unveil successful data from a late-stage Covid-19 vaccine trial, ahead of rival Moderna Inc. Pfizer and BioNTech launched their 44,000 volunteer phase 3 study of their vaccine candidate in late July.</p>.<p>The data monitoring board is scheduled to make its first assessment of the vaccine's performance after 32 participants in the trial become infected with the novel coronavirus.</p>.<p>As the pandemic crimps demand for certain Pfizer therapies and damages global economies, investors are keenly focused on seeing the late-stage study data of the vaccine candidate being developed with BioNTech.</p>.<p>Pfizer reported quarterly earnings that beat estimates by one cent, helped by better-than-expected sales of its cancer drug Ibrance.</p>.<p>Overall sales fell 4.3% in the third quarter, hurt by a plunge in sales of its off-patent pain drug Lyrica and a $500 million hit to sales from the Covid-19 pandemic.</p>.<p>Sales of cancer drug Ibrance grew 6% to $1.36 billion, beating analyst estimates of $1.39 billion, despite increased competition from Eli Lilly's Verzenio.</p>.<p>Excluding items, Pfizer earned 72 cents per share, beating analysts estimates of 71 cents per share, according to IBES data from Refinitiv.</p>